姓名：邓锡云

照片：

职称：教授

职务：基础医学系主任、基础医学博士/硕士学位点负责人

研究生招生专业：基础医学（博士学位）；病理学与病理生理学（硕士学位）；肿瘤学（硕士学位）

联系电话：0731-88912415（Office）

电子邮箱：dengxiyunmed@hunnu.edu.cn

简介：

邓锡云博士，教授、博士生导师、js555888金沙老品牌“世承人才”计划入选者；现任js555888金沙老品牌肿瘤干细胞与转化医学重点实验室主任、基础医学系主任兼博士/硕士学位点负责人。毕业于湘雅js555888金沙老品牌，在美国进行博士后研究并获得助理教授职位，于2012年全职引进至js555888金沙老品牌。长期从事肿瘤干细胞靶向药物的研发及作用机制、代谢重编程和肿瘤转移的分子机制等研究。率先提出用天然化合物针对三阴性乳腺癌干细胞进行靶向治疗；发现蛋白翻译后修饰介导药物诱导的肿瘤细胞应激反应并率先提出“反向核仁应激”（reverse nucleolar stress）的概念。

主持国家自然科学基金面上项目5项以及湖南省自然科学基金、长沙市科技项目、js555888金沙老品牌开放课题等多项科研课题；主编《Triple-Negative Breast Cancer（三阴性乳腺癌）》英文专著，由亚太地区规模最大的英文科技出版公司World Scientific Publishing出版；主编《Triple-Negative Breast Cancer》专刊1期；在Breast Cancer Research、InternationalJournal of Biological Sciences、Blood、Clinical Cancer Research、Cancer Treatment Reviews、ACS Applied Materials & Interfaces等高影响因子杂志发表科研论文或综述100余篇。

主要研究方向：

1.三阴性乳腺癌干细胞靶向药物的研发及作用机制

2.肿瘤微环境及代谢重编程

社会（学术）兼职：

1.肿瘤干细胞与转化医学校级重点实验室主任

2.Scientific Reports杂志编委

3.Journal of Cancer杂志编委

4.肿瘤药学杂志编委

5.js555888金沙老品牌学报（医学版）常务编委

6.中国病理生理学会肿瘤专业委员会委员

7.湖南省解剖学会副理事长

8.湖南省病理生理学会常务理事

9.湖南省病理生理学会肿瘤专业委员会副主任委员

10.中国抗癌协会会员

11.中国生物化学与分子生物学学会会员

获得的人才项目（荣誉）：

js555888金沙老品牌“世承人才”（2019年）

主持的科研项目：

（一）国家级项目

1.国家自然科学基金面上项目：核受体PXR在洛伐他汀促进三阴性乳腺癌干细胞对多柔比星敏感性中的作用及机制

批准号：82173374 起止日期：2022.01-2025.12 金额：55万元

2.国家自然科学基金面上项目：洛伐他汀通过核仁应激介导的自噬抑制三阴性乳腺癌干细胞作用的分子机制

批准号：81872167 起止日期：2019.01-2022.12 金额：58万元

3.国家自然科学基金面上项目：洛伐他汀靶向乳腺癌干细胞抑制EMT和转移的作用及机制

批准号：81472496 起止日期：2015.01-2018.12 金额：70万元

4.国家自然科学基金面上项目：EB病毒LMP1调节趋化因子受体CXCR4活性促进鼻咽癌转移的分子机制研究

批准号：30771966 起止日期：2008.01-2010.12 金额：32万元

5.国家自然科学基金面上项目：趋化因子受体EBI1/CCR7在鼻咽癌转移中的作用

批准号：30170877 起止日期：2002.01-2003.12 金额：16万元

（二）省厅级项目

1.湖南省自然科学基金面上项目：洛伐他汀通过上调p14ARF促进核仁应激抑制三阴性乳腺癌干细胞作用的机制研究

批准号：2019JJ40193 起止日期：2019.01-2021.12 金额：10万元

2.湖南省教育厅重点项目：莫那可林K靶向干细胞抑制乳腺癌转移的实验研究

批准号：14A089 起止日期：2014.09-2017.08 金额：6万元

（三）院校级项目

1.js555888金沙老品牌优秀回国人员科研启动基金：代谢调节分子AMPK在肿瘤转移中的作用及机制研究

批准号：130608 起止日期：2012.12-2022.11 金额：160万元

2.js555888金沙老品牌创新团队基金：基于肿瘤与生殖干细胞研究

批准号：KF2022004 起止日期：2023.07-2024.06 金额：10万元

3.js555888金沙老品牌创新团队基金：肿瘤与生殖干细胞基础与转化研究

批准号：KF2022002 起止日期：2022.07-2023.06 金额：16万元

代表性学术论文（#为并列第一作者，*为通讯作者)

1.Xiyun Deng, Hirotsugu Ueda, Shao Bo Su, Wanghua Gong, Nancy M. Dunlop, Ji-Liang Gao,Philip M. Murphy, Ji Ming Wang*. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R.Blood1999; 94(4):1165-1173.IF: 20.3

2.Jinyue Hu^#,Xiyun Deng^#, Xiuwu Bian, Guancheng Li, Yongqing Tong, Yuehui Li, Qingliang Wang, Rong Xin, Xiaojuan He, Guohua Zhou, Pingli Xie, Yanwen Li, Ji Ming Wang, Ya Cao*. The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma.Clinical Cancer Research2005; 11(13):4658-4665.IF: 11.5

3.Xiyun Deng, Guangchun He, Junwen Liu, Feijun Luo, Xiaoning Peng, Shigang Tang, Zhiyong Gao, Qinlu Lin, Jill M Keller, Tao Yang*, Evan T Keller*. Recent Advances in Bone-Targeted Therapies of Metastatic Prostate Cancer.Cancer Treatment Reviews2014; 40(6):730-738.IF: 11.8

4.Xinyu Wang, Chanjuan Zheng, Hui Yao, Yuxuan Guo, Yian Wang, Guangchun He, Shujun Fu,Xiyun Deng*. Disulfidptosis: Six Riddles Necessitating Solutions.International Journal of Biological Sciences2024; 20(3):1042-1044.IF:9.2

5.Liujiang Song^#, Xiaojun Tao^#, Li Lin^#, Chao Chen, Hui Yao, Guangchun He, Guangyang Zou, Zhong Cao, Shichao Yan, Lu Lu, Huimei Yi, Di Wu, Siyuan Tan, Wanxin Ouyang, Zhifei Dai*,Xiyun Deng*. Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells to Improve Therapeutic Efficacy.ACS Applied Materials & Interfaces2018; 10(8):7022-7030.IF: 8.9

6.Chanjuan Zheng#, Xi Xu#, Muyao Wu#, Lian Xue, Jianyu Zhu, Hongzhuo Xia, Siyu Ding, Shujun Fu, Xinyu Wang, Yian Wang, Guangchun He, Xia Liu*,Xiyun Deng*. Neutrophils in Triple-Negative Breast Cancer: An Underestimated Player with Increasingly Recognized Importance.Breast Cancer Research2023; 25(1):88.IF:7.3

7.Xiyun Deng*, Chanjuan Zheng, Faqing Tang, Thomas J Rosol, Zhi-Ming Shao*. Editorial: Triple-Negative Breast Cancer: Heterogeneity, Tumor Microenvironment and Targeted Therapy.Frontiers in Oncology2022; 12:1026566.

8.Sisi Chen, Ying Li, Muyao Wu, Lian Xue, Jianyu Zhu, Mi Wu, Qiuting Zhang, Guangchun He, Guifei Li, Shujun Fu, Chanjuan Zheng*,Xiyun Deng*. Nucleolar and Coiled-Body Phosphoprotein 1 (NOLC1) Is Associated with Stemness and Represents a Potential Therapeutic Target in Triple-Negative Breast Cancer.Frontiers in Oncology2022; 12:731528.

9.Mi Wu^#, Lu Lu^#, Sisi Chen, Ying Li, Qiuting Zhang, Shujun Fu*,Xiyun Deng*. Natural Products Inducing Nucleolar Stress: Implications in Cancer Therapy.Anticancer Drugs2022; 33(1):e21-e27.

10.Shichao Yan^#, Da Tang^#, Zhangyong Hong, Jing Wang, Hui Yao, Lu Lu, Huimei Yi, Shujun Fu, Chanjuan Zheng, Guangchun He, Heng Zou, Xuyang Hou, Qing He, Li Xiong*, Qinglong Li*,Xiyun Deng*. CD133 peptide-conjugated pyropheophorbide-a as a novel photosensitizer for targeted photodynamic therapy in colorectal cancer stem cells.Biomaterials Science2021; 9(6):2020-2031.IF: 6.6（封面文章）

11.Chanjuan Zheng^#, Shichao Yan^#, Lu Lu^#, Hui Yao, Guangchun He, Sisi Chen, Ying Li, Xiaojun Peng, Zhongyi Cheng, Mi Wu, Qiuting Zhang, Guifei Li, Shujun Fu,Xiyun Deng*. Lovastatin Inhibits EMT and MetastasisofTriple-Negative Breast Cancer Stem Cells ThroughDysregulation of Cytoskeleton-Associated Proteins.Frontiers in Oncology2021;11:656687.

12.Ying Li^#,Zhijun Zhan^#,Xuemin Yin,Shujun Fu*,Xiyun Deng*. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.Frontiers in Oncology2021;11:731535.

13.Huimei Yi^#, Ying Li^#,Yuan Tan^#, Shujun Fu*, Faqing Tang*,Xiyun Deng*. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.Frontiers in Oncology2021;11:648139.

14.Huimei Yi, Mi Wu, Qiuting Zhang, Lu Lu, Hui Yao, Sisi Chen, Ying Li, Chanjuan Zheng, Guangchun He,Xiyun Deng*. Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells.Journal of Cancer2020; 11(13): 3713-3716.

15.Di Wu^#, Yao Chen^#, Shun Wen, Yi Wen, Rong Wang, Qiuting Zhang, Ge Qin, Huimei Yi, Mi Wu, Lu Lu, Xiaojun Tao*,Xiyun Deng*. Synergistically enhanced inhibitory effects of pullulan nanoparticle-mediated co-delivery of lovastatin and doxorubicin to triple-negative breast cancer cells.Nanoscale Research Letters2019; 14(1):314-325.

16.Liang Zeng,Xiyun Deng*, Jingmin Zhong, Li Yuan, Xiaojun Tao, Sai Zhang, Yong Zeng, Guangchun He, Pingping Tan, Yongguang Tao*. Prognostic value of biomarkers EpCAM and αB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.BMC Cancer2019; 9(1):831-841.

17.Lu Lu^#, Huimei Yi^#, Chao Chen^#, Shichao Yan, Hui Yao, Guangchun He, Guifei Li, Yiqun Jiang, Tuo Deng,Xiyun Deng*. Nucleolar stress: is there a reverse version?Journal of Cancer2018; 9(20): 3723-3727.

18.Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J Rosol,Xiyun Deng*. Triple-Negative Breast Cancer: Is There a Treatment on the Horizon?Oncotarget2017; 8(1):1913-1924.

19.Liang Zeng, Jingmin Zhong, Guangchun He, Fangjun Li, Jing Li, Wen Zhou, Wenbin Liu, Yun Zhang, Sanqian Huang, Zhihong Liu,Xiyun Deng*. Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis.Journal of Cancer2017; 8(15):3062-3069.

20.Hui Yao, Guangchun He, Chao Chen, Shichao Yan, Lu Lu, Liujiang Song, K Vinod Vijayan, Qinglong Li, Li Xiong, Xiongying Miao,Xiyun Deng*. PAI1: a novel PP1-interacting protein that mediates human plasma's anti-apoptotic effect in endothelial cells.Journal of Cellular and Molecular Medicine2017; 21(9):2068-2076.IF: 5.3

21.Tao Yang, Hui Yao, Guangchun He, Liujiang Song, Ning Liu, Yan Wang, Yingke Yang, Evan T Keller,Xiyun Deng*. Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis.Journal of Cancer2016; 7(2):192-199.

22.Xiyun Deng, Yanna Cao, Yan Liu, Fazhi Li, Kamalanathan Sambandam, Srinivasan Rajaraman, Archibald S Perkins, Alan P Fields, Mark R Hellmich, Courtney M Townsend Jr, E Aubrey Thompson, Tien C Ko*. Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.Molecular Carcinogenesis2013; 52(4):255-264.

23.Xiyun Deng*, Guangchun He, Andrea Levine, Ya Cao, Chad Mullins. Adenovirus-mediated Expression of TIMP-1 and TIMP-2 in Bone Inhibits the Growth of Human Prostate Cancer.International Journal of Cancer2008; 122(1):209-218.IF: 6.4

24.Xiyun Deng, Sarah H Tannehill-Gregg, Murali V P Nadella, Guangchun He, Andrea Levine, Ya Cao, Thomas J Rosol*. Parathyroid Hormone-related Protein and Ezrin Are Up-regulated in Human Lung Cancer Bone Metastases.Clinical & Experimental Metastasis2007; 24(2):107-119.

25.Xiyun Deng*, Sunita Bhagat, Zhong Dong, Chadwick Mullins, Sreenivasa Rao Chinni, Michael Cher. Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel.European Journal of Cancer2006; 42(18):3267-3273.IF: 8.4

26.Xiyun Deng, Min Kim, Didier Vandier, Yun-jin Jung, Toshiki Rikiyama, Magda K Sgagias, Merrill Goldsmith, Kenneth H Cowan*. Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin.Biochemical & Biophysical Research Communications2002; 296(4):792-798.

科研获奖

湖南省自然科学奖三等奖项目名称：洛伐他汀靶向乳腺癌干细胞的作用和机制研究。（完成人：邓锡云、贺光春、姚慧、易慧媚、陆露、吴迪）

主编的专著及参编的书籍章节：

1.Xiyun Deng*, Faqing Tang*, Thomas J Rosol* (Editors):Triple-Negative Breast Cancer.Singapore: World Scientific Publishing, 2020 (ISBN 978-981-3277-75-5)

https://www.worldscientific.com/worldscibooks/10.1142/111990

微信推送：仁爱谨研，协同育人——金沙官网邓锡云教授出版三阴性乳腺癌《Triple-Negative Breast Cancer》专著 （js555888金沙老品牌 2021-10-04 23:41）

https://mp.weixin.qq.com/s/vRgyXPiCP-LUSxWnUBx1qA

2.Xiyun Deng*:Triple-negative breast cancer.InBreast Cancer.Berlin (Germany): Avid Science, 2016, pp. 1-33.

http://www.avidscience.com/wp-content/uploads/2016/06/BRSTC-16-01_June-03-2016.pdf

3.Xiyun Deng*, Jinlu Dai, Evan T Keller:Bone-targeted therapies of metastatic prostate cancer.InAdvances in Prostate Cancer.Berlin (Germany): Avid Science, 2016, pp. 1-47.

http://www.avidscience.com/wp-content/uploads/2017/01/RAPOC-15-01_Galley-Proof.pdf

4.陶永光、邓锡云：核酸分析技术。曹亚主编：实用分子生物学操作指南人民卫生出版社2003. pp. 70-129.

主编的SCI期刊专刊：

Xiyun Deng, Faqing Tang, Thomas J Rosol (Research Topic Editors): Triple-Negative Breast Cancer: Heterogeneity, Tumor Microenvironment and Targeted Therapy. Frontiers in Oncology 2021

https://www.frontiersin.org/research-topics/17273/triple-negative-breast-cancer-heterogeneity-tumor-microenvironment-and-targeted-therapy

获得的国家发明专利授权：

邓锡云、戴志飞、宋柳江、林利、姚慧、贺光春：一种靶向乳腺癌干细胞的洛伐他汀硅质体。国家发明专利（专利号：ZL201610072500.5，授权日期：2017.09）

人才培养：

（一）研究生培养

培养博士研究生5名，毕业博士研究生1名；培养硕士研究生18名，毕业硕士研究生12名。指导博士研究生和硕士研究生获得“癌变与侵袭原理研究国际会议”青年论坛一等奖、二等奖，湖南省解剖学会学术年会研究生论坛特等奖、国家奖学金及湖南省优秀研究生等。

（二）青年教师培养

指导青年教师获国家自然科学基金面上项目和青年基金6项。